Metabolic disease comprises a set of risk factors highly associated with obesity and insulin resistance and is a consequence of central adiposity, hyperglycemia, and dyslipidemia. Furthermore, obesity increases the risk of the development of metabolic disease due to ectopic fat deposition, low-grade inflammation, and systemic energy disorders caused by dysregulated adipose tissue function. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and has been reported to exhibit anticancer and anti-inflammatory properties. In addition, recently reported beneficial effects of piceatannol on hypercholesterolemia, atherosclerosis, and angiogenesis underscore its therapeutic potential in cardiovascular disease. However, investigation of its role in metabolic disease is still in its infancy. This review intensively summarizes in vitro and in vivo studies supporting the potential therapeutic effects of piceatannol in metabolic disease, including inhibition of adipogenesis and lipid metabolism in adipocytes, and regulation of hyperlipidemia, hyperglycemia, insulin resistance, and fatty acid-induced inflammation and oxidative stress.
Get full access to this article
View all access options for this article.
References
1.
AguilarM, BhuketT, TorresS, LiuB, WongRJ: Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA, 2015; 313:1973–1974.
2.
International Diabetes Federation: IDF worldwide definition of the metabolic syndrome, 2015. www.idf.org/metabolic-syndrome (accessed September2016).
3.
KaurJ: A comprehensive review on metabolic syndrome. Cardiol Res Pract, 2014; 2014:943162.
4.
BaurJA, PearsonKJ, PriceNL, et al.: Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006; 444:337–342.
5.
LagougeM, ArgmannC, Gerhart-HinesZ, et al.: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell, 2006; 127:1109–1122.
6.
LiuK, ZhouR, WangB, MiMT: Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. Am J Clin Nutr, 2014; 99:1510–1519.
7.
CarpeneC, Gomez-ZoritaS, DeleruyelleS, CarpeneMA: Novel strategies for preventing diabetes and obesity complications with natural polyphenols. Curr Med Chem, 2015; 22:150–164.
8.
WalleT: Bioavailability of resveratrol. Ann NY Acad Sci, 2011; 1215:9–15.
9.
SetoguchiY, OritaniY, ItoR, et al.: Absorption and metabolism of piceatannol in rats. J Agric Food Chem, 2014; 62:2541–2548.
10.
PiotrowskaH, KucinskaM, MuriasM: Biological activity of piceatannol: Leaving the shadow of resveratrol. Mutat Res, 2012; 750:60–82.
11.
TangYL, ChanSW: A review of the pharmacological effects of piceatannol on cardiovascular diseases. Phytother Res, 2014; 28:1581–1588.
12.
SeyedMA, JantanI, BukhariSN, VijayaraghavanK: A comprehensive review on the chemotherapeutic potential of piceatannol for cancer treatment, with mechanistic insights. J Agric Food Chem, 2016; 64:725–737.
13.
SurhYJ, NaHK: Therapeutic potential and molecular targets of piceatannol in chronic diseases. Adv Exp Med Biol, 2016; 928:185–211.
14.
VinasP, Martinez-CastilloN, CampilloN, Hernandez-CordobaM: Directly suspended droplet microextraction with in injection-port derivatization coupled to gas chromatography-mass spectrometry for the analysis of polyphenols in herbal infusions, fruits and functional foods. J Chromatogr A, 2011; 1218:639–646.
15.
MatsuiY, SugiyamaK, KameiM, et al.: Extract of passion fruit (Passiflora edulis) seed containing high amounts of piceatannol inhibits melanogenesis and promotes collagen synthesis. J Agric Food Chem, 2010; 58:11112–11118.
16.
RimandoAM, KaltW, MageeJB, DeweyJ, BallingtonJR: Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem, 2004; 52:4713–4719.
17.
KuKL, ChangPS, ChengYC, LienCY: Production of stilbenoids from the callus of Arachis hypogaea: A novel source of the anticancer compound piceatannol. J Agric Food Chem, 2005; 53:3877–3881.
18.
CantosE, EspinJC, FernandezMJ, OlivaJ, Tomas-BarberanFA: Postharvest UV-C-irradiated grapes as a potential source for producing stilbene-enriched red wines. J Agric Food Chem, 2003; 51:1208–1214.
19.
YangMH, LinYJ, KuoCH, KuKL: Medicinal mushroom Ganoderma lucidum as a potent elicitor in production of t-resveratrol and t-piceatannol in peanut calluses. J Agric Food Chem, 2010; 58:9518–9522.
20.
PotterGA, PattersonLH, WanoghoE, et al.: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer, 2002; 86:774–778.
21.
PiverB, FerM, VitracX, et al.: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol, 2004; 68:773–782.
22.
NilesRM, CookCP, MeadowsGG, FuYM, McLaughlinJL, RankinGO: Resveratrol is rapidly metabolized in athymic (Nu/Nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr, 2006; 136:2542–2546.
23.
LiF, SunY, SongM, WuX, XiaoH: Gastrointestinal biotransformation of resveratrol in mice. FASEB J, 2016; 30:145.7.
24.
RoupeKA, RemsbergCM, YanezJA, DaviesNM: Pharmacometrics of stilbenes: Seguing towards the clinic. Curr Clin Pharmacol, 2006; 1:81–101.
25.
RoupeK, TengXW, FuX, MeadowsGG, DaviesNM: Determination of piceatannol in rat serum and liver microsomes: Pharmacokinetics and phase I and II biotransformation. Biomed Chromatogr, 2004; 18:486–491.
26.
BillackB, RadkarV, AdiabouahC: In vitro evaluation of the cytotoxic and anti-proliferative properties of resveratrol and several of its analogs. Cell Mol Biol Lett, 2008; 13:553–569.
27.
MuriasM, JagerW, HandlerN, et al.: Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: Structure-activity relationship. Biochem Pharmacol, 2005; 69:903–912.
28.
KitaY, MiuraY, YagasakiK: Antiproliferative and anti-invasive effect of piceatannol, a polyphenol present in grapes and wine, against hepatoma AH109A cells. J Biomed Biotechnol, 2012; 2012:672416.
29.
AlmeidaL, Vaz-da-SilvaM, FalcaoA, et al.: Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res, 2009; 53:S7–S15.
30.
BrentsLK, Medina-BolivarF, SeelyKA, et al.: Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica, 2012; 42:139–156.
31.
LinHS, TringaliC, SpataforaC, WuC, HoPC: A simple and sensitive HPLC-UV method for the quantification of piceatannol analog trans-3,5,3′,4′-tetramethoxystilbene in rat plasma and its application for a pre-clinical pharmacokinetic study. J Pharm Biomed Anal, 2010; 51:679–684.
32.
MessiadH, Amira-GuebailiaH, HouacheO: Reversed phase high performance liquid chromatography used for the physicochemical and thermodynamic characterization of piceatannol/β-cyclodextrin complex. J Chromatogr B Analyt Technol Biomed Life Sci, 2013; 926:21–27.
33.
InagakiH, ItoR, SetoguchiY, OritaniY, ItoT: Administration of piceatannol complexed with α-cyclodextrin improves its absorption in rats. J Agric Food Chem, 2016; 64:3557–3563.
34.
Van GaalLF, MertensIL, De BlockCE: Mechanisms linking obesity with cardiovascular disease. Nature, 2006; 444:875–880.
35.
SpaldingKL, ArnerE, WestermarkPO, et al.: Dynamics of fat cell turnover in humans. Nature, 2008; 453:783–787.
36.
KwonJY, SeoSG, HeoYS, et al.: Piceatannol, natural polyphenolic stilbene, inhibits adipogenesis via modulation of mitotic clonal expansion and insulin receptor-dependent insulin signaling in early phase of differentiation. J Biol Chem, 2012; 287:11566–11578.
37.
HuangX, OrdemannJ, MullerJM, DubielW: The COP9 signalosome, cullin 3 and Keap1 supercomplex regulates CHOP stability and adipogenesis. Biol Open, 2012; 1:705–710.
38.
GeahlenRL, McLaughlinJL: Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun, 1989; 165:241–245.
39.
WangH, MalbonCC: Gsα repression of adipogenesis via Syk. J Biol Chem, 1999; 274:32159–32166.
40.
ArakakiN, KitaT, ShibataH, HigutiT: Cell-surface H+-ATP synthase as a potential molecular target for anti-obesity drugs. FEBS Lett, 2007; 581:3405–3409.
41.
KitaT, ArakakiN: Contribution of extracellular ATP on the cell-surface F1F0-ATP synthase-mediated intracellular triacylglycerol accumulation. Biomed Res, 2015; 36:115–120.
42.
ArakakiN, NagaoT, NikiR, et al.: Possible role of cell surface H+-ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol Cancer Res, 2003; 1:931–939.
43.
Les ParelladaF, DeleruyelleS, CassagnesLE, et al.: Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties. Chem Biol Interact, 2016; 258:115–125.
44.
HijonaE, AguirreL, Perez-MatuteP, et al.: Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: Gut microbiota, metabolic, endocrine, and cardiac aspects. J Physiol Biochem, 2016; 72:567–582.
45.
TungYC, LinYH, ChenHJ, et al.: Piceatannol exerts anti-obesity effects in C57BL/6 mice through modulating adipogenic proteins and gut microbiota. Molecules, 2016; 21:1419.
46.
MinakawaM, MiuraY, YagasakiK: Piceatannol, a resveratrol derivative, promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and suppresses blood glucose levels in type 2 diabetic model db/db mice. Biochem Biophys Res Commun, 2012; 422:469–475.
47.
Uchida-MarukiH, InagakiH, ItoR, KuritaI, SaiM, ItoT: Piceatannol lowers the blood glucose level in diabetic mice. Biol Pharm Bull, 2015; 38:629–633.
48.
MutabarukaMS, Aoulad AissaM, DelalandreA, LavigneM, LajeunesseD: Local leptin production in osteoarthritis subchondral osteoblasts may be responsible for their abnormal phenotypic expression. Arthritis Res Ther, 2010; 12:R20.
49.
OritaniY, OkitsuT, NishimuraE, SaiM, ItoT, TakeuchiS: Enhanced glucose tolerance by intravascularly administered piceatannol in freely moving healthy rats. Biochem Biophys Res Commun, 2016; 470:753–758.
50.
KobayashiK, IshiharaT, KhonoE, MiyaseT, YoshizakiF: Constituents of stem bark of Callistemon rigidus showing inhibitory effects on mouse α-amylase activity. Biol Pharm Bull, 2006; 29:1275–1277.
51.
TowlerMC, HardieDG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res, 2007; 100:328–341.
52.
SaltielAR, KahnCR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 2001; 414:799–806.
53.
JeongSO, SonY, LeeJH, et al.: Resveratrol analog piceatannol restores the palmitic acid-induced impairment of insulin signaling and production of endothelial nitric oxide via activation of anti-inflammatory and antioxidative heme oxygenase-1 in human endothelial cells. Mol Med Rep, 2015; 12:937–944.
MeigsJB, LarsonMG, FoxCS, KeaneyJFJr., VasanRS, BenjaminEJ: Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: The Framingham Offspring Study. Diabetes Care, 2007; 30:2529–2535.
56.
SamuelVT, ShulmanGI: Mechanisms for insulin resistance: Common threads and missing links. Cell, 2012; 148:852–871.
57.
LlarenaM, AndradeF, HasnaouiM, et al.: Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats. J Physiol Biochem, 2015; 72:555–566.
58.
SonY, ChungHT, PaeHO: Differential effects of resveratrol and its natural analogs, piceatannol and 3,5,4′-trans-trimethoxystilbene, on anti-inflammatory heme oxigenase-1 expression in RAW264.7 macrophages. Biofactors, 2014; 40:138–145.
WungBS, HsuMC, WuCC, HsiehCW: Piceatannol upregulates endothelial heme oxygenase-1 expression via novel protein kinase C and tyrosine kinase pathways. Pharmacol Res, 2006; 53:113–122.
61.
LeeHH, ParkSA, AlmazariI, KimEH, NaHK, SurhYJ: Piceatannol induces heme oxygenase-1 expression in human mammary epithelial cells through activation of ARE-driven Nrf2 signaling. Arch Biochem Biophys, 2010; 501:142–150.
62.
LiuFC, HwangTL, LauYT, YuHP: Mechanism of salutary effects of astringinin on rodent hepatic injury following trauma-hemorrhage: Akt-dependent hemeoxygenase-1 signaling pathways. PLoS One, 2011; 6:e25907.
63.
SonY, ByunSJ, PaeHO: Involvement of heme oxygenase-1 expression in neuroprotection by piceatannol, a natural analog and a metabolite of resveratrol, against glutamate-mediated oxidative injury in HT22 neuronal cells. Amino Acids, 2013; 45:393–401.
64.
JaisA, EinwallnerE, SharifO, et al.: Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell, 2014; 158:25–40.
65.
ChoHJ, ShimJH, SoHS, ParkJHY: Mechanism underlying the anti-inflammatory action of piceatannol induced by lipopolysaccharide. J Korean Soc Food Sci Nutr, 2012; 41:1226–1234.
66.
KwonGT, JungJI, SongHR, et al.: Piceatannol inhibits migration and invasion of prostate cancer cells: Possible mediation by decreased interleukin-6 signaling. J Nutr Biochem, 2012; 23:228–238.
67.
SuL, DavidM: Distinct mechanisms of STAT phosphorylation via the interferon-α/β receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem, 2000; 275:12661–12666.
68.
SchouM, DjurupR, NorrisK, FlodgaardH: Identifying the functional part of heparin-binding protein (HBP) as a monocyte stimulator and the novel role of monocytes as HBP producers. Innate Immun, 2011; 17:60–69.
69.
OlsnesC, StavangH, OlofssonJ, AarstadHJ: TNF-α is secreted by monocytes in transit to become macrophages, but not by peripheral blood monocytes, following OK-432 (lyophilized S. pyogenes) stimulation. Scand J Immunol, 2007; 66:684–693.
70.
FritzenwangerM, MeuselK, FoersterM, KuetheF, KrackA, FigullaHR: Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. Cytokine, 2006; 36:101–106.
71.
JinCY, MoonDO, LeeKJ, et al.: Piceatannol attenuates lipopolysaccharide-induced NF-κB activation and NF-κB-related proinflammatory mediators in BV2 microglia. Pharmacol Res, 2006; 54:461–467.
72.
RichardN, PorathD, RadspielerA, SchwagerJ: Effects of resveratrol, piceatannol, tri-acetoxystilbene, and genistein on the inflammatory response of human peripheral blood leukocytes. Mol Nutr Food Res, 2005; 49:431–442.
73.
UlanovaM, PuttaguntaL, Marcet-PalaciosM, et al.: Syk tyrosine kinase participates in β1-integrin signaling and inflammatory responses in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2005; 288:L497–L507.
74.
DangO, NavarroL, DavidM: Inhibition of lipopolysaccharide-induced interferon regulatory factor 3 activation and protection from septic shock by hydroxystilbenes. Shock, 2004; 21:470–475.
NeilsonAP, FerruzziMG: Bioavailability and metabolism of bioactive compounds from foods. In: Nutrition in the Prevention and Treatment of Disease (CoulstonAM, BousheyCJ, FerruzziMG, eds.) Elsevier, Atlanta, GA, USA, 2013, pp. 407–420.
77.
MiksitsM, SulyokM, SchuhmacherR, SzekeresT, JagerW: In-vitro sulfation of piceatannol by human liver cytosol and recombinant sulfotransferases. J Pharm Pharmacol, 2009; 61:185–191.
78.
MiksitsM, Maier-SalamonA, VoTP, et al.: Glucuronidation of piceatannol by human liver microsomes: Major role of UGT1A1, UGT1A8 and UGT1A10. J Pharm Pharmacol, 2010; 62:47–54.
79.
ZhengJ, RamirezVD: Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem Biophys Res Commun, 1999; 261:499–503.
80.
CordonierEL, AdjamR, TeixeiraDC, et al.: Resveratrol compounds inhibit human holocarboxylase synthetase and cause a lean phenotype in Drosophila melanogaster. J Nutr Biochem, 2015; 26:1379–1384.
81.
WanX, WangXB, YangMH, WangJS, KongLY: Dimerization of piceatannol by Momordica charantia peroxidase and α-glucosidase inhibitory activity of the biotransformation products. Bioorg Med Chem, 2011; 19:5085–5092.
82.
AshikawaK, MajumdarS, BanerjeeS, BhartiAC, ShishodiaS, AggarwalBB: Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation. J Immunol, 2002; 169:6490–6497.
83.
KawakamiS, KinoshitaY, Maruki-UchidaH, YanaeK, SaiM, ItoT: Piceatannol and its metabolite, isorhapontigenin, induce SIRT1 expression in THP-1 human monocytic cell line. Nutrients, 2014; 6:4794–4804.
84.
HowitzKT, BittermanKJ, CohenHY, et al.: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003; 425:191–196.
85.
HongKS, ParkJI, KimMJ, et al.: Involvement of SIRT1 in hypoxic down-regulation of c-Myc and β-catenin and hypoxic preconditioning effect of polyphenols. Toxicol Appl Pharmacol, 2012; 259:210–218.
